» Articles » PMID: 10988144

Immunohistochemical Staining for Chlamydia Pneumoniae is Increased in Lung Tissue from Subjects with Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2000 Sep 16
PMID 10988144
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The seroprevalence of Chlamydia pneumoniae is increased in chronic obstructive pulmonary disease (COPD), and subjects with COPD are more likely to have a positive polymerase chain reaction for C. pneumoniae in their sputum. It has been suggested that C. pneumoniae may have a role in the pathogenesis of COPD. We undertook immunohistochemistical staining for C. pneumoniae in archival tissue from subjects who had undergone lobectomy for bronchial carcinoma. There were 16 subjects with COPD (FEV(1) = 64 +/- 8% [mean +/- SD] predicted) and 21 subjects with normal lung function (FEV(1) = 95 +/- 11% predicted). There was no difference between the two groups in age or smoking history. Tissues from all of the subjects stained positively for C. pneumoniae, but in the subjects with COPD there were 14.5 positive cells per field (magnification x400), as compared with 9.3 cells per field in the control subjects (p = 0.02). Fifty-four percent of the macrophages from the subjects with COPD stained positively for C. pneumoniae, as compared with 29% from the control subjects (p < 0.001). A second control group consisted of 18 younger individuals (mean age: 32 yr) who died accidentally. Only 44% of these subjects had positive staining for C. pneumoniae, and the mean number of cells per field was 0.4. These findings suggest that persistent infection with C. pneumoniae is common, and that there is increased immunostaining for C. pneumoniae in COPD. Further studies are necessary to determine whether chronic infection with C. pneumoniae is important in the pathogenesis of COPD.

Citing Articles

Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease.

Zhu Y, Chang D Chronic Dis Transl Med. 2023; 9(2):104-121.

PMID: 37305112 PMC: 10249200. DOI: 10.1002/cdt3.66.


Chlamydia pneumoniae and chronic asthma: Updated systematic review and meta-analysis of population attributable risk.

Hahn D PLoS One. 2021; 16(4):e0250034.

PMID: 33872336 PMC: 8055030. DOI: 10.1371/journal.pone.0250034.


Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides.

Webley W, Hahn D Respir Res. 2017; 18(1):98.

PMID: 28526018 PMC: 5437656. DOI: 10.1186/s12931-017-0584-z.


A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.

Shafuddin E, Mills G, Holmes M, Poole P, Mullins P, Black P J Negat Results Biomed. 2015; 14:15.

PMID: 26346300 PMC: 4562194. DOI: 10.1186/s12952-015-0034-8.


Pneumocystis jirovecii colonization is associated with enhanced Th1 inflammatory gene expression in lungs of humans with chronic obstructive pulmonary disease.

Fitzpatrick M, Tedrow J, Hillenbrand M, Lucht L, Richards T, Norris K Microbiol Immunol. 2014; 58(3):202-11.

PMID: 24438206 PMC: 4106795. DOI: 10.1111/1348-0421.12135.